Key Highlights
- 15.56% is the indicated pre-market decline for SS Innovations International Inc. (NASDAQ:SSII) on November 17, 2026, taking the price to USD 1.14 from a calculated prior close of USD 1.35, a calculated move of negative USD 0.21.
- 11.1 million USD was first quarter 2026 revenue, up 116.8% from 5.1 million USD a year earlier, with gross Margin at 48.0% versus 21.2% and a net loss of USD 3.6 million versus USD 5.7 million.
- 26 SSi Mantra systems were installed in the first quarter, up 73.3%, lifting the installed base to 194 systems across 11 countries, with 1,859 surgeries in the quarter and 9,744 cumulative procedures.
- 42.48 million USD was fiscal 2025 revenue, up 105.74% from 20.65 million USD in 2024, while the fiscal 2025 net loss narrowed 36.68% to USD 12.13 million.
What Moved SS Innovations International Inc. (NASDAQ:SSII) in Pre-Market Trading on November 17, 2026 (-USD 0.21, -15.56%)
The indicated pre-market price for SS Innovations International Inc. (NASDAQ:SSII) is USD 1.14 on November 17, 2026, a pre-market move of -15.56%. The calculated prior close is USD 1.35 (USD 1.14 divided by 0.8444) and the calculated USD move is negative USD 0.21. Using 200.39 million shares outstanding from published market data, the calculated Market Value at the indicated price is about USD 228.45 million. Pre-market Volume figures were not found, and pre-market Liquidity is typically thin.
The Rationale: No Same-Day Catalyst Identified, With FDA 510(k) Review in Focus for SS Innovations International Inc. (NASDAQ:SSII)
No catalyst for the November 17, 2026 move was identified in published coverage. The company is a commercial-stage surgical robotics Business whose main product is the SSi Mantra system, supported by SSi Mudra instruments. On October 13, 2026 it submitted its response to an FDA request for additional information on its 510(k) submission. CEO Dr. Sudhir Srivastava has said the FDA review is expected to conclude in 2026 and that EU CE marking is also expected in 2026. Sarah M. Romano became chief financial officer effective August 3, 2026.
Valuation, Liquidity and Risks for SS Innovations International Inc. (NASDAQ:SSII)
Trailing twelve-month Revenue was USD 52.40 million with a net loss of USD 12.43 million. At March 31, 2026 the company reported USD 16.0 million of cash and a USD 11.2 million bank overdraft facility, and it raised about USD 18.6 million gross in a March 2026 private placement. A USD 150 million mixed securities shelf was reported on May 1, 2026, and published coverage in February 2026 described a USD 50 million share offering as dilutive. Regulatory timing, dilution and hospital-driven Capital spending are specific risks.
Where Things Stand
SS Innovations International Inc. (NASDAQ:SSII) is indicated down 15.56% in pre-market trading on November 17, 2026, at USD 1.14, a calculated USD 0.21 below a calculated prior close of USD 1.35. No specific catalyst was identified in published coverage. First quarter 2026 revenue was USD 11.1 million, up 116.8%, with Gross Profit of USD 5.3 million and a net loss of USD 3.6 million. The company expects FDA and EU decisions on the SSi Mantra in 2026, but timing is not guaranteed. Pre-market moves can reverse at the open, and this article is not Investment advice.






Please wait processing your request...